Medscape www.medscape.com

References for:
Antidepressant Discontinuation Syndromes: Common, Under-Recognised and Not Always Benign

[Drug Ther Perspect 17(20):12-15, 2001. © 2001 Adis International Limited]

  1. Haddad PM. Antidepressant discontinuation syndromes: clinical relevance, prevention and management. Drug Saf 2001; 24 (3): 183-97
  2. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998; 12 (3): 305-13
  3. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo controlled trial. Br J Psychiatry 2000; 176: 363-8
  4. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1991; 167: 374-9
  5. Fava M, Mulroy R, Alpert J, et al. Emergence of adverse effects following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154 (12): 1760-2
  6. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 1998; 44: 77-87
  7. Olver JS, Burrows GD, Norman TR. Discontinuation syndromes with selective serotonin reuptake inhibitors: are there clinically relevant differences? CNS Drugs 1999 Sep; 12 (3): 171-7
  8. Price JS, Waller PC, Wood SM, et al. A comparison of the postmarketing safety of four selective serotonin re-uptake inhibitors, including the investigation of symptoms occurring, on withdrawal. Br J Clin Pharmacol 1996; 42: 757-63
  9. British National Formulary. No. 41. London: The Pharmaceutical Press, 2001 Mar: 187
  10. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997; 58 Suppl. 7: 37-40
  11. Kent LSW, Laidlaw JDD. Suspected congenital sertraline dependence [letter]. Br J Psychiatry 1995; 167: 412-3